A phase II trial of Ifosfamide combination with recommended supportive therapy for recurrent SCLC in second-line and heavily treated setting-Reference-Cited by-同舟云学术

A phase II trial of Ifosfamide combination with recommended supportive therapy for recurrent SCLC in second-line and heavily treated setting

Published:2017-12-12 Issue:2 Volume:81 Page:339-345
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Tanaka Ichidai^ORCID,Kawada Kenji,Morise Masahiro,Hase Tetsunari,Hayashi Hiroaki,Sokai Akihiko,Fukatsu Asuki,Kondo Masashi,Nomura Fumio,Hasegawa Yoshinori

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/article/10.1007/s00280-017-3497-0/fulltext.html

Reference23 articles.

1. Toyoda Y, Nakayama T, Ioka A et al (2008) Trends in lung cancer incidence by histological type in Osaka, Japan. Jpn J Clin Oncol 38:534–539

2. Govindan R, Page N, Morgensztern D et al (2006) Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24:4539–4544

3. Ardizzoni A, Hansen H, Dombernowsky P et al (1997) Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 15:2090–2096

4. O’Brien ME, Ciuleanu TE, Tsekov H et al (2006) Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 24:5441–5447

5. Onoda S, Masuda N, Seto T et al (2006) Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol 24:5448–5453

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Evolving Scenario of ES-SCLC Management: From Biology to New Cancer Therapeutics;Genes;2024-05-27

2. Current and Emerging Treatment Options for Patients With Relapsed Small-cell Lung Carcinoma: A Systematic Literature Review;Clinical Lung Cancer;2023-05

3. Partner-Specific Drug Repositioning Approach Based on Graph Convolutional Network;IEEE Journal of Biomedical and Health Informatics;2022-11

Orphan Drugs in Development for the Treatment of Small-Cell Lung Cancer: Emerging Data on Lurbinectedin

;Lung Cancer: Targets and Therapy;2020-03

5. Irinotecan and Ifosfamide Combination is an Effective and Safe Option in Patients with Refractory Small Cell Lung Cancer: A Retrospective Cross-Sectional Study;Eurasian Journal of Medicine and Oncology;2020